InnovAge Holding Corp. — Form 10-Q Summary
Business context and reporting period
The filing covers the three months ended September 30, 2022, compared with the three months ended September 30, 2021. Although the request labels the period “2022 Q1,” the filing reports the quarter ended September 30, 2022 (InnovAge’s fiscal first quarter of fiscal 2023). InnovAge operates PACE programs, providing coordinated, fully capitated care to seniors. At quarter-end it served approximately 6,540 participants through 18 centers in five states.
Financial and operating performance
| Metric | Three months ended Sept. 30, 2022 | Prior-year period |
|---|---|---|
| Total revenue | $171.2 million | $173.1 million |
| Operating income (loss) | $(16.6) million | $11.7 million |
| Net income (loss) | $(13.7) million | $7.6 million |
| Net income (loss) attributable to InnovAge | $(13.1) million; $(0.10) per share | $7.7 million; $0.06 per share |
| Operating cash flow | $13.1 million | $20.6 million |
| Adjusted EBITDA (non-GAAP) | $(3.8) million; (2.2)% margin | $18.2 million; 10.5% margin |
- Capitation revenue was $170.9 million, down 0.9%. Member months fell 5.6%, partly offset by a 4.9% increase in capitation rates. Reported census was 6,540 versus 6,990 a year earlier.
- External provider costs increased 6.9% to $96.2 million, and cost of care rose 31.5% to $53.6 million. Combined, these costs were approximately 87% of revenue. Center-level contribution margin fell to $21.4 million, or 12.5% of revenue, from $42.3 million, or 24.5%.
- Corporate, general and administrative expense increased 43.1% to $30.2 million. Sales and marketing expense decreased 29.9% to $4.4 million.
- Cash and cash equivalents were $188.2 million at September 30, 2022. Net cash increased $3.8 million during the quarter. Operating cash flow included a $23.4 million increase in deferred revenue; investing cash outflow was $7.7 million, primarily for property and equipment.
- Total debt principal was approximately $72.6 million, including $70.3 million under the term loan and $2.3 million under a convertible loan. The $100 million revolving facility had no borrowings; disclosed remaining capacity was subject to letters of credit, covenants and other conditions. The company reported covenant compliance.
- Operating and finance lease liabilities totaled $36.3 million. InnovAge adopted the new lease accounting standard on July 1, 2022, recognizing operating lease assets of $23.0 million and liabilities of $24.1 million at quarter-end.
Material changes and management commentary
Management attributed the sharp deterioration in operating results primarily to higher medical and operating costs amid lower participant months. Provider costs reflected increased housing utilization and state-mandated rates. Center staffing costs rose with headcount and wage rates; compliance and audit support, transportation, and corporate capability investments also added expense. Management said inflation’s effect on results for the quarter was not material after mitigation efforts, but expected inflation and labor pressures to continue.
New-enrollment suspensions at Colorado centers and the Sacramento center constrained census and growth. The company had submitted attestations asserting that corrective action plans had been completed; regulatory validation was pending. Management stated that available cash, operating cash flows and financing sources were expected to fund operating and capital needs for the next 12 months and beyond, while cautioning that assumptions could prove incorrect. No numerical earnings or revenue guidance is provided.
Risks, contingencies and unusual items
- CMS and state agencies had suspended new enrollments in Colorado and Sacramento. Colorado validation was expected to begin in December 2022; CMS validation for Sacramento was expected to begin in November 2022. Timing and outcomes were uncertain. California had also suspended assurances for planned new centers pending remediation; the company cited restrictions or pauses affecting planned expansion in other states.
- The company was implementing corrective actions following audits in San Bernardino, California, and Albuquerque, New Mexico. CMS had indicated no enforcement action for the San Bernardino findings and no enforcement action for Albuquerque, but audit close-out work remained ongoing.
- InnovAge disclosed a putative shareholder class action alleging misleading statements and omissions, and civil investigative demands from Colorado’s Attorney General and the Department of Justice concerning Medicaid billing and PACE services. Outcomes were not predictable. A stockholder books-and-records demand was also pending.
- Adjusted EBITDA excludes items including $7.2 million of business-optimization costs and $0.6 million of EMR implementation costs in the quarter. These non-GAAP adjustments should be considered alongside GAAP results, not as a substitute for them.
- The filing gives inconsistent term-loan interest rates: 2.21% in the debt note, 3.38% in the liquidity discussion and 3.83% in the market-risk section. The applicable quarter-end rate is therefore unclear from the filing text.
- Management concluded disclosure controls and procedures were effective as of September 30, 2022 and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether Colorado and Sacramento regulators validate remediation and lift enrollment sanctions, and the resulting effect on participant months, revenue and center economics.
- Trends in external medical costs, staffing costs and contribution margin, including whether higher capitation rates can offset cost increases.
- The source and sustainability of operating cash flow, particularly the material deferred-revenue inflow, and cash requirements for remediation, leases and capital investment.
- Developments and potential financial exposure in the shareholder litigation and government investigations.
- The correct term-loan interest rate and borrowing availability under the revolving facility, given the filing’s differing rate disclosures.